Relapsed/Refractory Acute Myeloid Leukemia (AML)
Oncology·MeSH: Leukemia, Myeloid, Acute
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| rtx-240 | Rubius Therapeutics, Inc. (RUBY) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| CLN-049 | Cullinan Therapeutics, Inc. (CGEM) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Acute Myeloid Leukemia (AML)?
BioSniper tracks 2 drugs in development for Relapsed/Refractory Acute Myeloid Leukemia (AML) across 2 companies.
How many clinical trials target Relapsed/Refractory Acute Myeloid Leukemia (AML)?
There are 1 clinical trial targeting Relapsed/Refractory Acute Myeloid Leukemia (AML) tracked by BioSniper.
Deep-dive into Relapsed/Refractory Acute Myeloid Leukemia (AML)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis